Format

Send to

Choose Destination
Lancet Respir Med. 2014 Nov;2(11):933-942. doi: 10.1016/S2213-2600(14)70232-2. Epub 2014 Nov 3.

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

Author information

1
Department of Respiratory Medicine, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Leuven, Belgium.
2
Department of Thoracic Medicine and Laboratory of Cellular and Molecular Pneumonology, Medical School, University of Crete, Crete, Greece.
3
Inserm U1152, Université Paris Diderot, PRES Sorbonne Paris Cité, LabEx Inflamex, and Assistance Publique-Hôpitaux de Paris, DHU FIRE, Paris, France; Service de Pneumologie A, Centre de Compétence des Maladies Pulmonaires Rares, Hôpital Bichat, Paris, France.
4
Department of Pneumology/Allergology, Ruhrlandklinik, University Hospital, University Duisburg-Essen, Essen, Germany.
5
Hôpital Louis Pradel, Claude Bernard Lyon 1 University, Lyon, France.
6
Centre for Interstitial Lung Diseases and University Medical Center Utrecht, Department of Pulmonology, St. Antonius Hospital Nieuwegein, Netherlands.
7
NIHR Biological Research Unit, Royal Brompton Hospital, Sydney Street, London, UK.
8
Department of Diseases of the Thorax, Ospedale GB Morgagni, Forlì, Italy.
9
National Institute for Health Research, Southampton Respiratory Biomedical Research Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
10
Regional Centre for Interstitial and Rare Lung Diseases, Department of Clinical and Molecular Biomedicine, University of Catania, Catania, Italy.
11
Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK. Electronic address: athol.wells@rbht.nhs.uk.

Erratum in

Abstract

Findings from recently published placebo-controlled trials in idiopathic pulmonary fibrosis have established that pirfenidone and nintedanib prevent about 50% of the decline in forced vital capacity typically seen in this disease; future trials are therefore unlikely to use placebo as a control group for ethical reasons. Future clinical assessment will probably include add-on trials in which a new drug is combined with an intervention with established efficacy; this development is in turn likely to herald the use of combination regimens in clinical practice. Personalised medicine (the selection of monotherapies on the basis of individualised biomarker signal) is an intrinsically attractive alternative approach, but is unlikely to be useful in routine management of idiopathic pulmonary fibrosis in the medium-term future because of the complex nature of the disease's pathogenesis. In this Personal View, we review the pleiotropic nature of disease pathogenesis in idiopathic pulmonary disease, the use of combination regimens in other selected chronic lung diseases, and the conceptual basis for combination therapies in interstitial lung disorders other than idiopathic pulmonary fibrosis. On the basis of these considerations, and the emergence of data from add-on trials, we believe that the future of management for idiopathic pulmonary fibrosis lies in the development of combination regimens.

PMID:
25439569
DOI:
10.1016/S2213-2600(14)70232-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center